Dr. Reddy's Laboratories Revenue, Profits - RDY Annual Income Statement

Add to My Stocks
$36.73 $0.53 (1.46%) RDY stock closing price Sep 20, 2018 (Closing)

Looking at financial statements, along with the Dr. Reddy's Laboratories stock price, it's management, its economic moat, and industry competitors forms an important part of fundamental analysis. In the income statement, an investor can look at important parameters like revenue or sales, gross profits, net profits, and EPS basic to gain deeper insights. The income statement for RDY which shows a YOY revenue growth of 0.46% is specific to a period of time. Investors typically check YoY or QoQ revenue growth. The operating expenses as shown in the Dr. Reddy's Laboratories profit and loss statement for 2018 total to $989M. This line item shows that the operating expenses has decreased compared with last year. Also check: Dr. Reddy's Laboratories assets and Dr. Reddy's Laboratories free cash flow.

View revenue and profit details for latest and last 10 financial years.
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Apr - Mar2018201720162015201420132012201120102009
Dr. Reddy's Laboratories Revenues or Net Sales
2.18B2.17B2.34B2.38B2.2B2.13B1.9B1.68B1.56B1.37B
Cost Of Goods Sold (COGS)1.01B963M942M1.01B939M1.02B853M773M755M648M
Dr. Reddy's Laboratories Gross Profit
1.17B1.21B1.39B1.37B1.26B1.11B1.05B904M808M717M
Research & Development Expense281M301M269M280M207M141M116M114M84M79M
Selling General & Admin Expense708M699M677M668M622M616M567M532M501M413M
Income Before Depreciation Depletion Amortization183M208M447M422M434M355M365M258M223M225M
Depreciation Depletion Amortization----------
Non Operating Income49M29M37M48M10M43M-2M21M-177M-304M
Interest Expense13M12M75M18M------
Dr. Reddy's Laboratories Pretax Income
220M226M410M452M443M398M363M279M46M-79M
Provision for Income Taxes70M40M108M96M85M90M83M31M22M23M
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations150M186M302M356M359M308M280M248M24M-102M
Extraordinary Items & Discontinued Operations----------
Dr. Reddy's Laboratories Profit/ Loss (Net Income)
151M186M302M356M359M308M280M248M24M-102M
Average Shares used to compute Diluted EPS166.2M167.57M170.62M171.15M170.95M171.11M175.63M165.33M240M170M
Average Shares used to compute Basic EPS165.84M167.57M170.62M171.15M170.95M171.11M175.63M165.33M240M170M
Income Before Nonrecurring Items166.71M186M302M356M351M316M300M242M205M173M
Income from Nonrecurring Items-14.57M---8M-8M-19M6M-181M-275M
Dr. Reddy's Laboratories Earnings Per Share Basic Net
0.921.111.772.082.101.801.601.500.10-0.60
Dr. Reddy's Laboratories Earnings Per Share Diluted Net
0.921.111.772.082.101.801.601.500.10-0.60
EPS Diluted Before Nonrecurring Items1.011.111.772.082.051.851.711.460.851.02
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.290.280.290.270.230.230.590.220.110.07
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

Before investing one should read a report on Dr. Reddy's Laboratories stock analysis. It helps to look at the following income statement items:

  • Revenue: The money received by selling of goods or services comes under this line item. A YoY growth - See: Dr. Reddy's Laboratories revenue chart implies that the company is growing. It has been the case with Dr. Reddy's Laboratories. One must look at stocks with increasing revenues, and stay away from stocks whose revenues or sales are declining.
  • Bottom line: Most businesses like Dr. Reddy's Laboratories try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called statement of revenue and expense. The RDY financials along with Dr. Reddy's Laboratories historical stock prices provide a lot of details about the firm.

Dr. Reddy's Laboratories Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
28.92
PS Ratio (price sales ratio)
2.74
Operating Margin
12.8
Net Profit Margin
12.3
Dividend Yield
0.79%